Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Amicus Therapeutics stock

Learn how to easily invest in Amicus Therapeutics stock.

Amicus Therapeutics Inc is a biotechnology business based in the US. Amicus Therapeutics shares (FOLD) are listed on the NASDAQ and all prices are listed in US Dollars. Amicus Therapeutics employs 483 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Amicus Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – FOLD – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Amicus Therapeutics stock price (NASDAQ: FOLD)

Use our graph to track the performance of FOLD stocks over time.

Amicus Therapeutics shares at a glance

Information last updated 2022-01-18.
Latest market close$9.54
52-week range$8.40 - $22.15
50-day moving average $11.21
200-day moving average $10.41
Wall St. target price$17.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.90

Buy Amicus Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
$0 per year
Get a free stock valued up to $3500
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Amicus Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Amicus Therapeutics price performance over time

Historical closes compared with the close of $9.54 from 2022-01-19

1 week (2022-01-13) -3.73%
1 month (2021-12-16) N/A
3 months (2021-10-16) N/A
6 months (2021-07-20) 0.21%
1 year (2021-01-20) -54.64%
2 years (2020-01-17) -8.36%
3 years (2019-01-18) 12.31
5 years (2017-01-20) 79.32%

Amicus Therapeutics financials

Revenue TTM $293.9 million
Gross profit TTM $229.8 million
Return on assets TTM -13.05%
Return on equity TTM -68.47%
Profit margin -81.17%
Book value $1.35
Market capitalisation $2.9 billion

TTM: trailing 12 months

Amicus Therapeutics share dividends

We're not expecting Amicus Therapeutics to pay a dividend over the next 12 months.

Amicus Therapeutics share price volatility

Over the last 12 months, Amicus Therapeutics's shares have ranged in value from as little as $8.4 up to $22.15. A popular way to gauge a stock's volatility is its "beta".

FOLD.US volatility(beta: 1.21)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amicus Therapeutics's is 1.2098. This would suggest that Amicus Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Amicus Therapeutics overview

Amicus Therapeutics, Inc. , a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Frequently asked questions

What percentage of Amicus Therapeutics is owned by insiders or institutions?
Currently 0.605% of Amicus Therapeutics shares are held by insiders and 106.987% by institutions.
How many people work for Amicus Therapeutics?
Latest data suggests 483 work at Amicus Therapeutics.
When does the fiscal year end for Amicus Therapeutics?
Amicus Therapeutics's fiscal year ends in December.
Where is Amicus Therapeutics based?
Amicus Therapeutics's address is: 3675 Market Street, Philadelphia, PA, United States, 19104
What is Amicus Therapeutics's ISIN number?
Amicus Therapeutics's international securities identification number is: US03152W1099
What is Amicus Therapeutics's CUSIP number?
Amicus Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03152W109

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site